ClinicalTrials.gg
RecruitingNCT05838287PIOHFUpdated Sep 22, 2026

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

A Phase 4 interventional study of Pioglitazone and Placebo in Type 2 Diabetes Mellitus in Obese and Heart Failure With Preserved Ejection Fraction, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 1 site in United States. Open to participants aged 30 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by The University of Texas Health Science Center at San Antonio · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Planned enrollment
72nd of 122
78 · median 103
Started
2023
with 1 other
Phase 4
57 of 122
4 open now
Registered
117th of 122
by date
Lead sponsor
9 of 122
The University of Texas Health Science Center at San Antonio

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 72nd largest by planned enrollment, is one of 2 that started in 2023, is one of 57 in phase 4, and was the 117th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are:

  1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals.
  2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.
Read the detailed description

Either Pioglitazone or Placebo Pioglitazone will be administered during this study in this Type 2 Diabetic population with Heart Failure to examine if there are any beneficial effects on diastolic and systolic function.

Myocardial blood flow (MBF) is measured using a PET scan, then participants will be randomized to pioglitazone or a placebo to examine the effects of the study drug on the effects on the systolic and diastolic function of the heart. In addition, myocardial insulin sensitivity change will be measured as well as myocardial fat content. The ratio of ATP: PCr will also be measured.

03

Conditions studied

  • Type 2 Diabetes Mellitus in Obese
  • Heart Failure With Preserved Ejection Fraction
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged 30-70 years
  4. (BMI) of 27.5-40kg/m²
  5. of 6.5 to 10%
  6. Blood pressure of less than or equal to 145/65mmHg
  7. greater than 45 ml/min/1.73m²
  8. Subject must have HFpEF (EF > 50% by ECHO screening)
  9. class II-III heart failure
  10. Only T2D patients treated with diet/exercise, metformin, sulfonylurea, metformin/SU, DPP4i or insulin will be studied.
  11. For females of : use of highly effective for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional [4 weeks] after the end of study participation.
  12. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with history of osteoporosis or proliferative diabetic retinopathy
  2. Subjects with Heart failure due to restrictive or infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, severe valvular heart disease, etc. will be excluded
  3. Patients with symptomatic coronary artery disease.
  4. Subjects with significant change in diuretic management during the month prior to screening (defined by doubling of diuretic dose, or addition of another HF medication).
  5. Subjects treated with a GLP-1 RA or thiazolidinedione.
  6. Subjects treated with a SGLT2i
  7. Pregnancy or lactation
  8. Known allergic reactions to components of the study interventions.
  9. Any metal plates, parts, screws, shrapnel, pins in body, or cardiac (heart) pacemaker
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
78 participants (estimated)

Study arms

  • Active comparator
    Pioglitazone Administration Group

    Pioglitazone 15mg/day titrated to 30 mg/day at week 2 and to 45 mg/day at week 4

    Drug: Pioglitazone

  • Placebo comparator
    Placebo/Control Group

    Placebo

    Drug: Placebo

Interventions

  • Participants will be taking Pioglitazone tablets 1/day for 24 weeks.

    Also known as: Actos

  • DrugPlacebo

    Placebo for Pioglitazone

    Also known as: Placebo tablet

06

What researchers measure

Primary outcomes

  1. Change in Systolic function

    Measurement of change in systolic function of the heart using cardiac MRI

    Time frame: Baseline and 6-months post treatment (approximately 24 weeks)

  2. Change in Diastolic function

    Measurement of change in diastolic function of the heart using cardiac MRI

    Time frame: Baseline and 6-months post treatment (approximately 24 weeks)

Secondary outcomes

  1. Myocardial insulin sensitivity

    Measurement of change in Free Plasma Glucose (FPG) in blood plasma

    Time frame: Baseline and 6-months post treatment (approximately 24 weeks)

  2. Myocardial fat content

    Measurement of change in myocardial fat content

    Time frame: Baseline and 6-months post treatment (approximately 24 weeks)

  3. PCr:ATP ratio

    Measurement of change in PCr:ATP ratio

    Time frame: Baseline and 6-months post treatment (approximately 24 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD data will not be available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Aug 2029, 73 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 73 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2023
First posted
May 1, 2023
StartActual
Jul 10, 2023
Primary completionEst.
Aug 2029
CompletionEst.
Jan 2030
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05838287
Responsible party
Sponsor
First posted
May 1, 2023
Start date
Jul 10, 2023
Primary completion
Aug 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Sep 22, 2026

Study contacts

Sivaram Neppala, MD
Contact
neppalas@uthscsa.edu
210-358-7200
Andrea Hansis-Diarte, MPH
Contact
Hansisdiarte@uthscsa.edu
210-567-3208
Ralph A DeFronzo, MD
principal investigator · University of Texas

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion